Codexis delivered strong revenues of $15.3 million, primarily due to variability in customer manufacturing schedules and timing in clinical trial progression, which impacted Pharma Biocatalysis order ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Codexis CDXS will release its quarterly earnings report on Wednesday, 2025-08-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Codexis to report an earnings per ...
Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies REDWOOD CITY, Calif., ...
REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE)-- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today ...
As of Sept. 30, institutional investors held over 86% of the outstanding shares. These include big names like BlackRock, Vanguard, and Fidelity as well as healthcare specialist funds including Vivo ...
Key Insights Significantly high institutional ownership implies Codexis' stock price is sensitive to their trading... Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, ...
REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointments ...
Codexis has built its reputation on engineering enzymes for various applications, but its recent focus on the enzymatic manufacturing of siRNA therapies marks a significant evolution in its business ...
REDWOOD CITY, Calif. and BEVERLY, Mass.--(BUSINESS WIRE)--Codexis, Inc. (Nasdaq: CDXS) and seqWell, Inc. today announced the initiation of a strategic partnership and investment to accelerate the ...
REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results